Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02222324 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT02222324 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 60 participants.
The verdict
NCT02222324, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This thorough QT (TQT) study will take place in healthy subjects administered single doses of study drug. It will be a randomized, double-blind, placebo and active-controlled, 4-treatment crossover study. Subjects will be randomized in an equal ratio to one of 12 possible treatment sequences. Each treatment sequence will comprise all 4 treatments.
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG E2609
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-08 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02222324
The ClinicalTrials.gov registry entry for NCT02222324 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02222324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02222324 about?
NCT02222324 is a clinical study titled "A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects". This thorough QT (TQT) study will take place in healthy subjects administered single doses of study drug. It will be a randomized, double-blind, placebo and active-controlled, 4-treatment crossover study. Subjects will be randomized in an equal ratio to one of 12 possible treatment sequences. Each t...
What is the current status of trial NCT02222324?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2014-08. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02222324?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), E2609 (DRUG).
Who is sponsoring clinical trial NCT02222324?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.